Publications

Rossi M, Martinengo B, Diamanti E, Salerno A, Rizzardi N, Fato R, Bergamini C, Souza de Oliveira A, Ferreira TAM, Holanda CA, Romeiro LAS, Soeiro MNC, Nunes K, Almeida Fiuza LF, Batista MM, Fraga CAM, Alkhalaf HEA, Elmahallawy EK, Ebiloma GU, De Koning HP, Vittorio S, Vistoli G, Blanquart C, Bertrand P, Bolognesi ML. Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic Diseases. ACS Med. Chem. Lett. 2024, 15, 1506−1515

Albertini, C., Petralla, S., Massenzio, F., Monti, B., Rizzardi, N., Bergamini, C., Uliassi, E., Borges, F., Chavarria, D., Fricker, G. and Goettert, M., 2024. Targeting Lewy body dementia with neflamapimod‐rasagiline hybrids. Archiv der Pharmazie, 357(6), p.2300525.

Calza, L., Giardino, L., Focarete, M.L., Gualandi, C., Bolognesi, M.L., Passerini, N., Pagliuca, G., Gazzotti, T. and Zironi, E., Universita di Bologna, 2024. Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug. U.S. Patent 11,992,560.

B Martinengo, E Diamanti, E Uliassi, ML Bolognesi - Harnessing the 12 Green Chemistry Principles for Sustainable Antiparasitic Drugs: Toward the One Health Approach, ACS Infectious Diseases. ACS Infect. Dis. 2024, 10, 1856−1870

Sarabia-Vallejo, Á., Molina, A., Martínez-Orts, M., D’Onofrio, A., Staderini, M., Bolognesi, M. L., ... & Menéndez, J. C. (2024). Fluorimetric Detection of Insulin Misfolding by Probes Derived from Functionalized Fluorene Frameworks. Molecules, 29(6), 1196.

Bayraktar, G., Bartolini, M., Bolognesi, M. L., Erdoğan, M. A., Armağan, G., Bayır, E., ... & Alptüzün, V. (2024). Novel multifunctional tacrine–donepezil hybrids against Alzheimer's disease: Design synthesis and bioactivity studies. Archiv der Pharmazie, e2300575.

Exertier, C., Salerno, A., Antonelli, L., Fiorillo, A., Ocello, R., Seghetti, F., ... & Bolognesi, M. L. (2024). Fragment Merging, Growing, and Linking Identify New Trypanothione Reductase Inhibitors for Leishmaniasis. Journal of Medicinal Chemistry, 67(1), 402-419.

Blanco, M. J., Bronson, J. J., DiMauro, E. F., Dzierba, C., Eggen, M., Garner, A. L., ... & Young, W. (2024). Empowering Voices: Inspiring Women in Medicinal Chemistry. Journal of medicinal chemistry, 67(6), 4251-4258.

Melissa Guardigni, Giulia Greco, Eleonora Poeta, Alan Santini, Elisa Tassinari, Christian Bergamini, Chiara Zalambani, Angela De Simone, Vincenza Andrisano, Elisa Uliassi, Barbara Monti, Maria Laura Bolognesi, Carmela Fimognari, Andrea Milelli - Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer - RSC Medicinal Chemistry, 2024

Pasieka, A., Diamanti, E., Uliassi, E., & Laura Bolognesi, M. (2023). Click chemistry and targeted degradation: a winning combination for medicinal chemists?. ChemMedChem, 18(20), e202300422.

González‐González, A., Vázquez, C., Encalada, R., Saavedra, E., Vázquez‐Jiménez, L. K., Ortiz‐Pérez, E., ... & Rivera, G. (2023). Phenothiazine‐based virtual screening, molecular docking, and molecular dynamics of new trypanothione reductase inhibitors of Trypanosoma cruzi. Molecular Informatics, 42(10), 2300069.

Uliassi, E., Bergamini, C., Rizzardi, N., Naldi, M., Cores, Á., Bartolini, M., ... & Bolognesi, M. L. (2023). Quinolinetrione-tacrine hybrids as multi-target-directed ligands against Alzheimer's disease. Bioorganic & Medicinal Chemistry, 91, 117419.

Nunes Lemes LF, Magoulas GE, Souza de Oliveira A, Barrias E, de Camargo Nascente L, Granado R, Teixeira de Macedo Silva S, Assimomytis N, de Souza W, Bolognesi ML, Romeiro LAS, Calogeropoulou T. Valorizing Constituents of Cashew Nut Shell Liquid toward the Sustainable Development of New Drugs against Chagas Disease. ACS Infect Dis. 2023 Jun 12.

Guardigni M, Pruccoli L, Santini A, De Simone A, Bersani M, Spyrakis F, Frabetti F, Uliassi E, Andrisano V, Pagliarani B, Fernández-Gómez P, Palomo V, Bolognesi ML, Tarozzi A, and Milelli A. PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer’s Disease. ACS Chem. Neurosci. 2023, 14, 11, 1963–1970.

Leggi dettagli

Uliassi E, Nikolic L, Bolognesi ML, Legname G. Therapeutic strategies for identifying small molecules against prion diseases. Cell Tissue Res. 2023 Apr;392(1):337-347.

Staderini M, Vanni S, Baldeschi AC, Giachin G, Zattoni M, Celauro L, Ferracin C, Bistaffa E, Moda F, Pérez DI, Martínez A, Martín MA, Martín-Cámara O, Cores Á, Bianchini G, Kammerer R, Menéndez JC, Legname G, Bolognesi ML. Bifunctional carbazole derivatives for simultaneous therapy and fluorescence imaging in prion disease murine cell models. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114923.

Espinoza-Chávez, R. M., Salerno, A., Liuzzi, A., Ilari, A., Milelli, A., Uliassi, E., & Bolognesi, M. L. Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery. ACS Bio & Med Chem Au. 2022 Dec 15; 3 (1): 32–45.

Bianco MDCAD, Inacio Leite D, Silva Castelo Branco F, Boechat N, Uliassi E, Bolognesi ML, Bastos MM. The Use of Zidovudine Pharmacophore in Multi-Target-Directed Ligands for AIDS Therapy. Molecules. 2022 Dec 3;27(23):8502.

Gandini A, Gonçalves AE, Strocchi S, Albertini C, Janočková J, Tramarin A, Grifoni D, Poeta E, Soukup O, Muñoz-Torrero D, Monti B, Sabaté R, Bartolini M, Legname G, Bolognesi ML. Discovery of Dual Aβ/Tau Inhibitors and Evaluation of Their Therapeutic Effect on a Drosophila Model of Alzheimer's Disease. ACS Chem Neurosci. 2022 Dec 7;13(23):3314-3329.

González-González A, Sánchez-Sánchez O, Krauth-Siegel RL, Bolognesi ML, Gớmez-Escobedo R, Nogueda-Torres B, Vázquez-Jiménez LK, Saavedra E, Encalada R, Espinoza-Hicks JC, Paz-González AD, Rivera G. In Vitro and In Silico Analysis of New n-Butyl and Isobutyl Quinoxaline-7-carboxylate 1,4-di-N-oxide Derivatives against Trypanosoma cruzi as Trypanothione Reductase Inhibitors. Int J Mol Sci. 2022 Nov 1;23(21):13315.

Albertini C, Salerno A, Atzeni S, Uliassi E, Massenzio F, Maruca A, Rocca R, Mecava M, Silva FSG, Mena D, Valente P, Duarte AI, Chavarria D, Bissaro M, Moro S, Federico S, Spalluto G, Soukup O, Borges F, Alcaro S, Monti B, Oliveira PJ, Menéndez JC, Bolognesi ML. Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis. ACS Chem Neurosci. 2022 Aug 3;13(15):2252-2260.

Salerno A, Seghetti F, Caciolla J, Uliassi E, Testi E, Guardigni M, Roberti M, Milelli A, Bolognesi ML. Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One. J Med Chem. 2022 Jul 28;65(14):9507-9530.

Colini Baldeschi A, Zattoni M, Vanni S, Nikolic L, Ferracin C, La Sala G, Summa M, Bertorelli R, Bertozzi SM, Giachin G, Carloni P, Bolognesi ML, De Vivo M, Legname G. Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance. J Med Chem. 2022 Jul 14;65(13):8998-9010.

Lauriola A, Uliassi E, Santucci M, Bolognesi ML, Mor M, Scalvini L, Elisi GM, Gozzi G, Tagliazucchi L, Marverti G, Ferrari S, Losi L, D'Arca D, Costi MP. Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library. Pharmaceutics. 2022 Feb 10;14(2):391.

Uliassi E, Nikolic L, Bolognesi ML, Legname G. Therapeutic strategies for identifying small molecules against prion diseases. Cell Tissue Res. 2022 Jan 6.

Lauriola A, Uliassi E, Santucci M, Bolognesi ML, Mor M, Scalvini L, Elisi GM, Gozzi G, Tagliazucchi L, Marverti G, Ferrari S, Losi L, D'Arca D, Costi MP. Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library. Pharmaceutics. 2022 Feb 10;14(2):391.

Bolognesi ML, Conway SJ. Celebrating the Medicinal Chemistry of Gunda Georg and Shaomeng Wang. J Med Chem. 2021 Dec 23;64(24):17541-17544.

Pont C.,Ginex T.,Griñán-Ferré C.,Scheiner M.,Mattellone A.,Martínez N.,Arce E.M.,Soriano-Fernández Y.,Naldi M.,De Simone A.,Barenys M.,Gómez-Catalán J., Pérez B.,Sabate R.,Andrisano V.,Loza M.,Brea J.,Bartolini M.,Bolognesi M.L.,Decker M.,Pallàs M.,Luque F.J.,Muñoz-Torrero D. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. European Journal of Medicinal Chemistry, 2021, 225, 113779

González-González A, Vazquez-Jimenez LK, Paz-González AD, Bolognesi ML, Rivera G. Recent Advances in the Medicinal Chemistry of Phenothiazines, New Anticancer and Antiprotozoal Agents. Curr Med Chem. 2021;28(38):7910-7936.

Uliassi, E., de Oliveira, A.S., Nascente, L.C., Romeiro, L.A.S., Bolognesi, M.L. Cashew nut shell liquid (Cnsl) as a source of drugs for alzheimer’s disease. Molecules, 2021, 26(18), 5441

Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML. From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology. Med Res Rev. 2021 Sep;41(5):2606-2633.

Fox, K., Luque, R., Soares Romeiro, L. A., & Bolognesi, M. L. "New Biomass Reagents for the Synthesis of Bioactive Compounds." Flow Chemistry in Drug Discovery. Cham: Springer International Publishing, 2021. 373-389.

Lindsley CW, Barrow J, Chibale K, Bolognesi ML, Conway S, Denny W, Ding K, Laufer S, Lai L, Liu H, Neamati N, Suzuki T, Meanwell N, Young W. Simplifying Submission Requirements for the Journal of Medicinal Chemistry. J Med Chem. 2021 Jun 24;64(12):7877-7878.

Dolci, L. S.; Perone, R. C.; Di Gesù, R.; Kurakula, M.; Gualandi, C.; Zironi, E.; Gazzotti, T.; Tondo, M. T.; Pagliuca, G.; Gostynska, N.; Baldassarro, V. A.; Cescatti, M.; Giardino, L.; Focarete, M. L.; Calzà, L.; Passerini, N.; Bolognesi, M. L., Design and In Vitro Study of a Dual Drug-Loaded Delivery System Produced by Electrospinning for the Treatment of Acute Injuries of the Central Nervous System. Pharmaceutics 2021, 13 (6).

Gorecki, L.; Uliassi, E.; Bartolini, M.; Janockova, J.; Hrabinova, M.; Hepnarova, V.; Prchal, L.; Muckova, L.; Pejchal, J.; Karasova, J. Z.; Mezeiova, E.; Benkova, M.; Kobrlova, T.; Soukup, O.; Petralla, S.; Monti, B.; Korabecny, J.; Bolognesi, M. L., Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer's Disease. ACS Chem Neurosci 2021, 12 (9), 1698-1715.

Rossi, M.; Freschi, M.; de Camargo Nascente, L.; Salerno, A.; de Melo Viana Teixeira, S.; Nachon, F.; Chantegreil, F.; Soukup, O.; Prchal, L.; Malaguti, M.; Bergamini, C.; Bartolini, M.; Angeloni, C.; Hrelia, S.; Soares Romeiro, L. A.; Bolognesi, M. L., Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. J Med Chem 2021, 64 (8), 4972-4990.

Schilf, P., Srinivasulu, V., Bolognesi, M. L., Ibrahim, S., Majdalawieh, A. F., Abu-Yousef, I. A., ... & Al-Tel, T. H. (2021). Design and synthesis of nature-inspired chromenopyrroles as potential modulators of mitochondrial metabolism. Medicinal Chemistry Research, 30, 635-646.

Albertini, C.; Naldi, M.; Petralla, S.; Strocchi, S.; Grifoni, D.; Monti, B.; Bartolini, M.; Bolognesi, M. L., From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease. Molecules 2021, 26 (4).

Perone R, Albertini C, Uliassi E, Di Pietri F, de Sena Murteira Pinheiro P, Petralla S, Rizzardi N, Fato R, Pulkrabkova L, Soukup O, Tramarin A, Bartolini M, Bolognesi M.L.Turning Donepezil into a Multi-Target-Directed Ligand through a Merging Strategy. ChemMedChem 16, 1, 2021, 187-198

Pont C, Ginex T, Griñán-Ferré C, Scheiner M, Mattellone A, Martínez N, Arce EM, Soriano-Fernández Y, Naldi M, De Simone A, Barenys M, Gómez-Catalán J, Pérez B, Sabate R, Andrisano V, Loza MI, Brea J, Bartolini M, Bolognesi ML, Decker M, Pallàs M, Luque FJ, Muñoz-Torrero D. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. Eur J Med Chem. 2021 Dec 5;225:113779.

Espro C, Paone E, Mauriello F, Gotti R, Uliassi E, Bolognesi ML, Rodríguez-Padrón D, Luque R. Sustainable production of pharmaceutical, nutraceutical and bioactive compounds from biomass and waste. Chem Soc Rev. 2021 Oct 18;50(20):11191-11207.

Ramos, G.; de Oliveira, A.; Bartolini, M.; Naldi, M.; Liparulo, I.; Bergamini, C.; Uliassi, E.; Wu, L.; Fraser, P.; Abreu, M.; Kiametis, A.; Gargano, R.; Silveira, E.; Brand, G.; Prchal, L.; Soukup, O.; Korabecny, J.; Bolognesi, M.; Romeiro, L., Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties. Rsc Medicinal Chemistry 2021, 12 (7), 1154-1163.

Rodrigues, D. A.; Pinheiro, P. S. M.; Sagrillo, F. S.; Bolognesi, M. L.; Fraga, C. A. M., Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. Med Res Rev 2020, 40 (6), 2177-2211.

Rossi M, Petralla S, Protti M, Baiula M, Kobrlova T, Soukup O, Spampinato S.M, Mercolini L, Monti B, Bolognesi M.L. α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis. ACS Med Chem Letters, 2020, 11(12), pp. 2406–2413

Zaccagnini L, Rossetti G, Tran TH, Salzano G, Gandini A, Colini Baldeschi A, Bolognesi ML, Carloni P, Legname G. In silico/in vitro screening and hit evaluation identified new phenothiazine anti-prion derivatives. Eur J Med Chem. 2020 Jun 15;196:112295.

Marques CS, López Ó, Bagetta D, Carreiro EP, Petralla S, Bartolini M, Hoffmann M, Alcaro S, Monti B, Bolognesi ML, Decker M, Fernández-Bolaños JG, Burke AJ. N-1,2,3-triazole-isatin derivatives for cholinesterase and β-amyloid aggregation inhibition: A comprehensive bioassay study. Bioorg Chem. 2020 May;98:103753.

Huryn DM, Bolognesi ML. A Different Kind of Medicinal Chemistry Toolbox. ACS Med Chem Lett. 2020 Mar 12;11(3):245-248.

Linciano P, Cullia G, Borsari C, Santucci M, Ferrari S, Witt G, Gul S, Kuzikov M, Ellinger B, Santarém N, Cordeiro da Silva A, Conti P, Bolognesi ML, Roberti M, Prati F, Bartoccini F, Retini M, Piersanti G, Cavalli A, Goldoni L, Bertozzi SM, Bertozzi F, Brambilla E, Rizzo V, Piomelli D, Pinto A, Bandiera T, Costi MP. Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. Eur J Med Chem. 2020 Mar 1;189:112047.

Bolognesi ML, Ganamet KL, Liu H, Poulsen SA, Georg GI, Wang S. Women in Medicinal Chemistry: Ad Maiora! J Med Chem. 2020 Mar 12;63(5):1777-1778.

Bolognesi ML, Rossi M. Multitarget Drug Discovery. eLS. 2020:1-7.

Al-Tel T.H, Srinivasulu V, Ramanathan M, Soares N.C, Sebastian A, Bolognesi M.L, Abu-Yousef I.A, Majdalawieh A. Stereocontrolled transformations of cyclohexadienone derivatives to access stereochemically rich and natural product-inspired architectures. Org Biomol Chem 2020, 18 (42), 8526-8571.

Lanthier C, Payan H, Liparulo I, Hatat B, Lecoutey C, Since M, Davis A, Bergamini C, Claeysen S, Dallemagne P, Bolognesi ML, Rochais C. Novel multi target-directed ligands targeting 5-HT(4) receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease. Eur J Med Chem. 2019 Nov 15;182:111596.

Roldán-Peña JM, Romero-Real V, Hicke J, Maya I, Franconetti A, Lagunes I, Padrón JM, Petralla S, Poeta E, Naldi M, Bartolini M, Monti B, Bolognesi ML, López Ó, Fernández-Bolaños JG. Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors. Eur J Med Chem. 2019 Nov 1;181:111550.

Moda F, Bolognesi ML, Legname G. Novel screening approaches for human prion diseases drug discovery. Expert Opin Drug Discov. 2019 Oct;14(10):983-993.

Janockova J, Gorecky L, Korabecny J, Bolognesi ML, Bartolini M, Soukup O. In vitro aggregation of the tau protein and its inhibition. InFEBS OPEN BIO 2019 Jul 1 (Vol. 9, pp. 223-223). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.

Ivasiv V, Albertini C, Gonçalves AE, Rossi M, Bolognesi ML. Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. Curr Top Med Chem. 2019;19(19):1694-1711.

Staderini M, Piquero M, Abengózar MÁ, Nachér-Vázquez M, Romanelli G, López-Alvarado P, Rivas L, Bolognesi ML, Menéndez JC. Structure-activity relationships and mechanistic studies of novel mitochondria-targeted, leishmanicidal derivatives of the 4-aminostyrylquinoline scaffold. Eur J Med Chem. 2019 Jun 1;171:38-53.

Chalupova K, Korabecny J, Bartolini M, Monti B, Lamba D, Caliandro R, Pesaresi A, Brazzolotto X, Gastellier AJ, Nachon F, Pejchal J, Jarosova M, Hepnarova V, Jun D, Hrabinova M, Dolezal R, Zdarova Karasova J, Mzik M, Kristofikova Z, Misik J, Muckova L, Jost P, Soukup O, Benkova M, Setnicka V, Habartova L, Chvojkova M, Kleteckova L, Vales K, Mezeiova E, Uliassi E, Valis M, Nepovimova E, Bolognesi ML, Kuca K. Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease. Eur J Med Chem.

Bolognesi ML, Ganamet KL, Liu H, Poulsen SA, Georg GI, Wang S. Women in Medicinal Chemistry Special Issue Call for Papers. J Med Chem. 2019 Apr 25;62(8):3783.

Soares Romeiro LA, da Costa Nunes JL, de Oliveira Miranda C, Simões Heyn Roth Cardoso G, de Oliveira AS, Gandini A, Kobrlova T, Soukup O, Rossi M, Senger J, Jung M, Gervasoni S, Vistoli G, Petralla S, Massenzio F, Monti B, Bolognesi ML. Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease. ACS Med Chem Lett. 2019 Mar 29;10(4):671-676.

Cerone M, Uliassi E, Prati F, Ebiloma GU, Lemgruber L, Bergamini C, Watson DG, de A M Ferreira T, Roth Cardoso GSH, Soares Romeiro LA, de Koning HP, Bolognesi ML. Discovery of Sustainable Drugs for Neglected Tropical Diseases: Cashew Nut Shell Liquid (CNSL)-Based Hybrids Target Mitochondrial Function and ATP Production in Trypanosoma brucei. ChemMedChem. 2019 Mar 22;14(6):621-635.

Moraes CB, Witt G, Kuzikov M, Ellinger B, Calogeropoulou T, Prousis KC, Mangani S, Di Pisa F, Landi G, Iacono LD, Pozzi C, Freitas-Junior LH, Dos Santos Pascoalino B, Bertolacini CP, Behrens B, Keminer O, Leu J, Wolf M, Reinshagen J, Cordeiro-da-Silva A, Santarem N, Venturelli A, Wrigley S, Karunakaran D, Kebede B, Pöhner I, Müller W, Panecka-Hofman J, Wade RC, Fenske M, Clos J, Alunda JM, Corral MJ, Uliassi E, Bolognesi ML, Linciano P, Quotadamo A, Ferrari S, Santucci M, Borsari C, Costi MP, Gul S. Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS Discov. 2019 Mar;24(3):346-361.

Alcaro S, Bolognesi ML, García-Sosa AT, Rapposelli S. Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation. Front Chem. 2019 Feb 18;7:71. doi: 10.3389/fchem.2019.00071. eCollection 2019.

Bolognesi ML. Harnessing Polypharmacology with Medicinal Chemistry. ACS Med Chem Lett. 2019 Feb 15;10(3):273-275.

Bolognesi, M. L. (2019). Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry. In Annual Reports in Medicinal Chemistry (Vol. 52, pp. 153-176). Academic Press.

Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018 Jan 17;7(1):3.

Uliassi E, Peña-Altamira LE, Morales AV, Massenzio F, Petralla S, Rossi M, Roberti M, Martinez Gonzalez L, Martinez A, Monti B, Bolognesi ML. A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. ACS Chem Neurosci. 2019 Jan 16;10(1):279-294.

Elisi GM, Santucci M, D'Arca D, Lauriola A, Marverti G, Losi L, Scalvini L, Bolognesi ML, Mor M, Costi MP. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers (Basel). 2018 Sep 14;10(9).

Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez C, Zuccheri G, Miti A, Feoli A, Castellano S, Petralla S, Monti B, Rossi M, Moda F, Legname G, Martinez A, Bolognesi ML. Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. J Med Chem. 2018 Sep 13;61(17):7640-7656.

Chioua M, Buzzi E, Moraleda I, Iriepa I, Maj M, Wnorowski A, Giovannini C, Tramarin A, Portali F, Ismaili L, López-Alvarado P, Bolognesi ML, Jóźwiak K, Menéndez JC, Marco-Contelles J, Bartolini M. Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. Eur J Med Chem. 2018 Jul 15;155:839-846.

Ortuso F, Bagetta D, Maruca A, Talarico C, Bolognesi ML, Haider N, Borges F, Bryant S, Langer T, Senderowitz H, Alcaro S. The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing. Front Chem. 2018 Apr 19;6:130.

Uliassi E, Piazzi L, Belluti F, Mazzanti A, Kaiser M, Brun R, Moraes CB, Freitas-Junior LH, Gul S, Kuzikov M, Ellinger B, Borsari C, Costi MP, Bolognesi ML. Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. ChemMedChem. 2018 Apr 6;13(7):678-683.

Prati F, Bottegoni G, Bolognesi ML, Cavalli A. BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease. J Med Chem. 2018 Feb 8;61(3):619-637.

Terra, B. S., da Silva, P. H., Tramarin, A., Franco, L. L., da Cunha, E. F., Macedo Junior, F., ... & Fátima, Â. D. (2018). Two Novel Donepezil-Lipoic Acid Hybrids: Synthesis, Anticholinesterase and Antioxidant Activities and Theoretical Studies. Journal of the Brazilian Chemical Society, 29, 738-747.

Uliassi E, Fiorani G, Krauth-Siegel RL, Bergamini C, Fato R, Bianchini G, Carlos Menéndez J, Molina MT, López-Montero E, Falchi F, Cavalli A, Gul S, Kuzikov M, Ellinger B, Witt G, Moraes CB, Freitas-Junior LH, Borsari C, Costi MP, Bolognesi ML. Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity. Eur J Med Chem. 2017 Dec 1;141:138-148.

Gandini, A., Prati, F., Uliassi, E., & Bolognesi, M. L. (2017). Drug Discovery Strategies for the Generation of Multitarget Ligands against Neglected Tropical Diseases. Drug Selectivity: An Evolving Concept in Medicinal Chemistry, 135-159.

Bolognesi, M. L. (2017, October). Sustainable Multi-Target Drugs for Neglected Tropical Diseases Caused by Trypanosomatids: Dream or Reality?. In Proceedings (Vol. 1, No. 6, p. 664). MDPI.

Uliassi, E., Piazzi, L., Belluti, F., Kaiser, M., Brun, R., Gul, S., ... & Bolognesi, M. L. (2017, October). Design, Synthesis and Structure—Activity Relationships of a Phenotypic Small Library against Protozoan Infections. In Proceedings (Vol. 1, No. 6, p. 648). MDPI.

Roldán-Peña JM, Alejandre-Ramos D, López Ó, Maya I, Lagunes I, Padrón JM, Peña-Altamira LE, Bartolini M, Monti B, Bolognesi ML, Fernández-Bolaños JG. New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents. Eur J Med Chem. 2017 Sep 29;138:761-773

Huryn DM, Bolognesi ML, Young WB. Medicinal Chemistry: Where Are All the Women? ACS Med Chem Lett. 2017 Aug 25;8(9):900-902.

Bruno, S., Uliassi, E., Zaffagnini, M., Prati, F., Bergamini, C., Amorati, R., ... & Bolognesi, M. L. (2017). Molecular basis for covalent inhibition of glyceraldehyde‐3‐phosphate dehydrogenase by a 2‐phenoxy‐1, 4‐naphthoquinone small molecule. Chemical biology & drug design, 90(2), 225-235.

Peña-Altamira E, Petralla S, Massenzio F, Virgili M, Bolognesi ML, Monti B. Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer's Disease. Front Aging Neurosci. 2017 Jun 7;9:175.

Uliassi, E., Gandini, A., Perone, R. C., & Bolognesi, M. L. (2017). Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery. Future medicinal chemistry, 9(10), 995-1013.

Bolognesi, M. L. (2017). Neurodegenerative drug discovery: Building on the past, looking to the future. Future Medicinal Chemistry, 9(8), 707-709.

Jeřábek J, Uliassi E, Guidotti L, Korábečný J, Soukup O, Sepsova V, Hrabinova M, Kuča K, Bartolini M, Peña-Altamira LE, Petralla S, Monti B, Roberti M, Bolognesi ML. Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease. Eur J Med Chem. 2017 Feb 15;127:250-262.

Chacón-Vargas KF, Nogueda-Torres B, Sánchez-Torres LE, Suarez-Contreras E, Villalobos-Rocha JC, Torres-Martinez Y, Lara-Ramirez EE, Fiorani G, Krauth-Siegel RL, Bolognesi ML, Monge A, Rivera G. Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors. Molecules. 2017 Feb 1;22(2):220.

Bolognesi, M. L. "From imaging agents to theranostic drugs in Alzheimer’s disease." (2017): 74-106.

Gandini A, Bolognesi ML. Therapeutic Approaches to Prion Diseases. Prog Mol Biol Transl Sci. 2017;150:433-453.

Uliassi, E., Prati, F., Bongarzone, S., & Bolognesi, M. L. (2017). Medicinal chemistry of hybrids for neurodegenerative diseases. In Design of Hybrid Molecules for Drug Development (pp. 259-277). Elsevier.

Silva RO, de Oliveira AS, Nunes Lemes LF, de Camargo Nascente L, Coelho do Nascimento Nogueira P, Silveira ER, Brand GD, Vistoli G, Cilia A, Poggesi E, Buccioni M, Marucci G, Bolognesi ML, Romeiro LAS. Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor. Eur J Med Chem. 2016 Oct 21;122:601-610.

Bolognesi ML, Gandini A, Prati F, Uliassi E. From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease? J Med Chem. 2016 Sep 8;59(17):7759-70.

Bolognesi, M. L., & Cavalli, A. (2016). Multitarget drug discovery and polypharmacology. ChemMedChem, 11(12), 1190-1192.

Prati, F., Bergamini, C., Fato, R., Soukup, O., Korabecny, J., Andrisano, V., ... & Bolognesi, M. L. (2016). Novel 8‐hydroxyquinoline derivatives as multitarget compounds for the treatment of Alzheimer′ s disease. ChemMedChem, 11(12), 1284-1295.

Peña-Altamira E, Prati F, Massenzio F, Virgili M, Contestabile A, Bolognesi ML, Monti B. Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation. Expert Opin Ther Targets. 2016;20(5):627-40.

Prati F, Cavalli A, Bolognesi ML. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease. Molecules. 2016 Apr 8;21(4):466.

Lemes LFN, de Andrade Ramos G, de Oliveira AS, da Silva FMR, de Castro Couto G, da Silva Boni M, Guimarães MJR, Souza INO, Bartolini M, Andrisano V, do Nascimento Nogueira PC, Silveira ER, Brand GD, Soukup O, Korábečný J, Romeiro NC, Castro NG, Bolognesi ML, Romeiro LAS. Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. Eur J Med Chem. 2016 Jan 27;108:687-700.

de Vin F, Choi SM, Bolognesi ML, Lefebvre RA. Presynaptic M3 muscarinic cholinoceptors mediate inhibition of excitatory synaptic transmission in area CA1 of rat hippocampus. Brain Res. 2015 Dec 10;1629:260-9.

Prati F, De Simone A, Armirotti A, Summa M, Pizzirani D, Scarpelli R, Bertozzi SM, Perez DI, Andrisano V, Perez-Castillo A, Monti B, Massenzio F, Polito L, Racchi M, Sabatino P, Bottegoni G, Martinez A, Cavalli A, Bolognesi ML. 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease. ACS Chem Neurosci. 2015 Oct 21;6(10):1665-82.

Bolognesi ML, Bongarzone S, Aulic S, Ai Tran HN, Prati F, Carloni P, Legname G. Rational approach to an antiprion compound with a multiple mechanism of action. Future Med Chem. 2015;7(16):2113-20.

Prati F, Bergamini C, Molina MT, Falchi F, Cavalli A, Kaiser M, Brun R, Fato R, Bolognesi ML. 2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile. J Med Chem. 2015 Aug 27;58(16):6422-34.

Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi E, Costi MP. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015 Jun 25;58(12):4857-73.

Bolognesi ML, Legname G. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead. Expert Opin Drug Discov. 2015 Apr;10(4):389-97.

Benchekroun M, Bartolini M, Egea J, Romero A, Soriano E, Pudlo M, Luzet V, Andrisano V, Jimeno ML, López MG, Wehle S, Gharbi T, Refouvelet B, de Andrés L, Herrera-Arozamena C, Monti B, Bolognesi ML, Rodríguez-Franco MI, Decker M, Marco-Contelles J, Ismaili L. Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids. ChemMedChem. 2015 Mar;10(3):523-39.

Prati F, De Simone A, Bisignano P, Armirotti A, Summa M, Pizzirani D, Scarpelli R, Perez DI, Andrisano V, Perez-Castillo A, Monti B, Massenzio F, Polito L, Racchi M, Favia AD, Bottegoni G, Martinez A, Bolognesi ML, Cavalli A. Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. Angew Chem Int Ed Engl. 2015 Jan 26;54(5):1578-82.

Staderini, M., Bolognesi, M. L., & Menéndez, J. C. (2015). Lewis Acid‐Catalyzed Generation of C C and C N Bonds on π‐Deficient Heterocyclic Substrates. Advanced Synthesis & Catalysis, 357(1), 185-195.

Staderini M, Martín MA, Bolognesi ML, Menéndez JC. Imaging of β-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscience. Chem Soc Rev. 2015 Apr 7;44(7):1807-19.

Nepovimova E, Uliassi E, Korabecny J, Peña-Altamira LE, Samez S, Pesaresi A, Garcia GE, Bartolini M, Andrisano V, Bergamini C, Fato R, Lamba D, Roberti M, Kuca K, Monti B, Bolognesi ML. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J Med Chem. 2014 Oct 23;57(20):8576-89.

Prati F, Goldman-Pinkovich A, Lizzi F, Belluti F, Koren R, Zilberstein D, Bolognesi ML. Quinone-amino acid conjugates targeting Leishmania amino acid transporters. PLoS One. 2014 Sep 25;9(9):e107994.

Bongarzone S, Staderini M, Bolognesi ML. Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. Future Med Chem. 2014 Jun;6(9):1017-29.

Bolognesi ML, Bergamini C, Fato R, Oiry J, Vasseur JJ, Smietana M. Synthesis of new lipoic acid conjugates and evaluation of their free radical scavenging and neuroprotective activities. Chem Biol Drug Des. 2014 Jun;83(6):688-96.

Belluti F, Uliassi E, Veronesi G, Bergamini C, Kaiser M, Brun R, Viola A, Fato R, Michels PA, Krauth-Siegel RL, Cavalli A, Bolognesi ML. Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. ChemMedChem. 2014 Feb;9(2):371-82.

Prati, F., & Bolognesi, M. L. (2014). Phenotypic Hits in Anti-Trypanosoma Drug Discovery. Chimica Ricerca.

Prati, F., Uliassi, E., & Bolognesi, M. L. (2014). Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases. MedChemComm, 5(7), 853-861.

Bolognesi, M. L. (2013). Amyloid chemical probes and theranostics: steps toward personalized medicine in neurodegenerative diseases. Medicinal Chemistry Approaches to Personalized Medicine, 211-226.

Prati F, Bartolini M, Simoni E, De Simone A, Pinto A, Andrisano V, Bolognesi ML. Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer's disease. Bioorg Med Chem Lett. 2013 Dec 1;23(23):6254-8.

Aulić S, Bolognesi ML, Legname G. Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int J Cell Biol. 2013;2013:150952.

Belluti F, Perozzo R, Lauciello L, Colizzi F, Kostrewa D, Bisi A, Gobbi S, Rampa A, Bolognesi ML, Recanatini M, Brun R, Scapozza L, Cavalli A. Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI). J Med Chem. 2013 Oct 10;56(19):7516-26.

Staderini M, Legname G, Bolognesi ML, Menéndez JC. Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. Curr Top Med Chem. 2013;13(19):2491-503.

Legname, G., & Laura Bolognesi, M. (2013). Editorial (Thematic issue: Recent advances of biology and medicinal chemistry of prion protein and prions: on the road to therapeutics). Current Topics in Medicinal Chemistry, 13(19), 2395-2396.

Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V. Multifunctional tacrine derivatives in Alzheimer's disease. Curr Top Med Chem. 2013;13(15):1771-86.

Rosini M, Simoni E, Bartolini M, Soriano E, Marco-Contelles J, Andrisano V, Monti B, Windisch M, Hutter-Paier B, McClymont DW, Mellor IR, Bolognesi ML. The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. ChemMedChem. 2013 Aug;8(8):1276-81.

Capurro V, Busquet P, Lopes JP, Bertorelli R, Tarozzo G, Bolognesi ML, Piomelli D, Reggiani A, Cavalli A. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. PLoS One. 2013;8(2):e56870.

Staderini M, Aulić S, Bartolini M, Tran HN, González-Ruiz V, Pérez DI, Cabezas N, Martínez A, Martín MA, Andrisano V, Legname G, Menéndez JC, Bolognesi ML. A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. ACS Med Chem Lett. 2012 Dec 28;4(2):225-9.

Staderini, M., Cabezas, N., Bolognesi, M. L., & Menéndez, J. C. (2013). Solvent-and chromatography-free amination of π-deficient nitrogen heterocycles under microwave irradiation. A fast, efficient and green route to 9-aminoacridines, 4-aminoquinolines and 4-aminoquinazolines and its application to the synthesis of the drugs amsacrine and bistacrine. Tetrahedron, 69(3), 1024-1030.

Pieretti S, Haanstra JR, Mazet M, Perozzo R, Bergamini C, Prati F, Fato R, Lenaz G, Capranico G, Brun R, Bakker BM, Michels PA, Scapozza L, Bolognesi ML, Cavalli A. Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism. PLoS Negl Trop Dis. 2013;7(1):e2012.

Lizzi F, Veronesi G, Belluti F, Bergamini C, López-Sánchez A, Kaiser M, Brun R, Krauth-Siegel RL, Hall DG, Rivas L, Bolognesi ML. Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile. J Med Chem. 2012 Dec 13;55(23):10490-500.

Gamberini MT, Bolognesi ML, Nasello AG. The modulatory role of M2 muscarinic receptor on apomorphine-induced yawning and genital grooming. Neurosci Lett. 2012 Dec 7;531(2):91-5.

Bolognesi, M. L., Melchiorre, C., Van der Schyf, C. J., & Youdim, M. (2012). Discovery of multi-target agents for neurological diseases via ligand design (pp. 290-315). The Royal Society of Chemistry, London, UK.

Cavalli, A., & Bolognesi, M. L. (2012). Multitargeted Drugs for Treatment of Alzheimer's Disease. Polypharmacology in drug discovery, 441-458.

Chiriano G, De Simone A, Mancini F, Perez DI, Cavalli A, Bolognesi ML, Legname G, Martinez A, Andrisano V, Carloni P, Roberti M. A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. Eur J Med Chem. 2012 Feb;48:206-13.

Minarini A, Milelli A, Tumiatti V, Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Motori E, Angeloni C, Hrelia S. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. Neuropharmacology. 2012 Feb;62(2):997-1003.

Simoni, E., Rosini, M., Bartolini, M., Andrisano, V., Soriano, E., Marco Contelles, J., ... & Bolognesi, M. L. (2012). Rational design of dimebon bivalent ligands against Alzheimer’s disease. In Libro degli abstracts (pp. 38-38). sl.

Staderini, M., Aulic, S., Bartolini, M., Tran, H. N. A., Ruiz, V. G., Pérez, D. I., ... & Bolognesi, M. L. (2012). Styrylquinoline derivatives potentially useful as diagnostic and therapeutic agents in misfolding diseases. In 2nd Meeting of the Paul Ehrlich MedChem Euro-PhD Network: 9th-11th September 2012, Ljubljana, Slovenia:[book of abstracts]. SVN.

Bolognesi ML, Chiriano G, Bartolini M, Mancini F, Bottegoni G, Maestri V, Czvitkovich S, Windisch M, Cavalli A, Minarini A, Rosini M, Tumiatti V, Andrisano V, Melchiorre C. Synthesis of monomeric derivatives to probe memoquin's bivalent interactions. J Med Chem. 2011 Dec 22;54(24):8299-304.

Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, Melchiorre C. Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease. Curr Top Med Chem. 2011 Nov;11(22):2797-806.

Bolognesi ML. Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases. Curr Top Med Chem. 2011 Nov;11(22):2824-33.

Rosini M, Simoni E, Bartolini M, Tarozzi A, Matera R, Milelli A, Hrelia P, Andrisano V, Bolognesi ML, Melchiorre C. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur J Med Chem. 2011 Nov;46(11):5435-42.

Staderini, M., Cabezas, N., Bolognesi, M. L., & Menéndez, J. C. (2011). A general protocol for the solvent-and catalyst-free synthesis of 2-styrylquinolines under focused microwave irradiation. Synlett, 2011(17), 2577-2579.

Bolognesi ML, Bartolini M, Tarozzi A, Morroni F, Lizzi F, Milelli A, Minarini A, Rosini M, Hrelia P, Andrisano V, Melchiorre C. Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg Med Chem Lett. 2011 May 1;21(9):2655-8.

Cristalli G, Bolognesi ML. Remembering Marie Curie's legacy. ChemMedChem. 2011 Apr 4;6(4):575-7.

Bongarzone S, Tran HN, Cavalli A, Roberti M, Rosini M, Carloni P, Legname G, Bolognesi ML. Hybrid lipoic acid derivatives to attack prion disease on multiple fronts. ChemMedChem. 2011 Apr 4;6(4):601-5.

Chiriano G, Sartini A, Mancini F, Andrisano V, Bolognesi ML, Roberti M, Recanatini M, Carloni P, Cavalli A. Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. Chem Biol Drug Des. 2011 Apr;77(4):268-71.

Bongarzone S, Bolognesi ML. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin Drug Discov. 2011 Mar;6(3):251-68.

Staderini, M., Cabezas, N., Bolognesi, M., Legname, G., & Menéndez, J. (2011). Styrylquinoline derivatives as therapeutic agents in prion disease. In 1st Meeting of the Paul Ehrlich MedChem Euro-PhD Network-7th Meeting of the European Network of Doctoral Studies in Pharmaceutical Sciences.

Staderini, M., Nowodworska, A., Tran, H., Cabezas, N., Bongarzone, S., Carloni, P., ... & Bolognesi, M. (2011). GN8 fluorescent analogues as chemical probes for prion diseases. In XXIV Congresso Nazionale della Società Chimica Italiana.

Bongarzone S, Tran HN, Cavalli A, Roberti M, Carloni P, Legname G, Bolognesi ML. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J Med Chem. 2010 Nov 25;53(22):8197-201.

Simoni E, Bergamini C, Fato R, Tarozzi A, Bains S, Motterlini R, Cavalli A, Bolognesi ML, Minarini A, Hrelia P, Lenaz G, Rosini M, Melchiorre C. Polyamine conjugation of curcumin analogues toward the discovery of mitochondria-directed neuroprotective agents. J Med Chem. 2010 Oct 14;53(19):7264-8.

Melchiorre C, Bolognesi ML, Minarini A, Rosini M, Tumiatti V. Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy. J Med Chem. 2010 Aug 26;53(16):5906-14.

Bolognesi ML, Ai Tran HN, Staderini M, Monaco A, López-Cobeñas A, Bongarzone S, Biarnés X, López-Alvarado P, Cabezas N, Caramelli M, Carloni P, Menéndez JC, Legname G. Discovery of a class of diketopiperazines as antiprion compounds. ChemMedChem. 2010 Aug 2;5(8):1324-34.

Bolognesi ML, Bartolini M, Mancini F, Chiriano G, Ceccarini L, Rosini M, Milelli A, Tumiatti V, Andrisano V, Melchiorre C. Bis(7)-tacrine derivatives as multitarget-directed ligands: Focus on anticholinesterase and antiamyloid activities. ChemMedChem. 2010 Aug 2;5(8):1215-20.

Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer's disease. Curr Med Chem. 2010;17(17):1825-38.

Bolognesi, M. L., Minarini, A., & Melchiorre, C. (2010). Discovery of Memoquin, a Multitarget-Directed Ligand (MTDL) for the Treatment of Alzheimer's Disease. In Emerging Drugs and Targets for Alzheimer’s Disease (pp. 213-227).

Tran HN, Bongarzone S, Carloni P, Legname G, Bolognesi ML. Synthesis and evaluation of a library of 2,5-bisdiamino-benzoquinone derivatives as probes to modulate protein-protein interactions in prions. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1866-8.

Cavalli A, Lizzi F, Bongarzone S, Belluti F, Piazzi L, Bolognesi ML. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. FEMS Immunol Med Microbiol. 2010 Feb;58(1):51-60.

Minarini A, Milelli A, Tumiatti V, Rosini M, Bolognesi ML, Melchiorre C. Synthetic polyamines: an overview of their multiple biological activities. Amino Acids. 2010 Feb;38(2):383-92.

Bolognesi, M. L. (2010). DESIGN OF BIFUNCTIONAL SMALL MOLECULES MODULATING PROTEIN-PROTEIN INTERACTIONS IN PRION DISEASES. In XX National Meeting on Medicinal Chemistry (pp. 18-18). ITA.

Bolognesi, M. L. (2010). From target-based to multi-target-based drug design approaches for neglected tropical diseases. In Program and Abstracts Proteine 2010 (pp. O-11). ITA.

Bolognesi ML, Cavalli A, Bergamini C, Fato R, Lenaz G, Rosini M, Bartolini M, Andrisano V, Melchiorre C. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6.

Cavalli A, Bolognesi ML. Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem. 2009 Dec 10;52(23):7339-59.

Bolognesi ML. β-Amyloid (Aβ); acetylcholinesterase (AChE); butyrylcholinesterase (BChE).

Rosini, M., Bartolini, M., Simoni, E., Gotti, C., McClymont, D. W., Bolognesi, M. L., ... & Melchiorre, C. (2009, October). MULTI-TARGET-DIRECTED LIGANDS AS ACETYLCHOLINESTERASE INHIBITORS AND NICOTINIC MODULATORS FOR ALZHEIMER'S DISEASE. In DRUGS OF THE FUTURE (Vol. 34, pp. 195-195). 398 PROVENCA, 08025 BARCELONA, SPAIN: PROUS SCIENCE, SAU-THOMSON REUTERS.

Andrisano, V., Bartolini, M., Bolognesi, M. L., Cavalli, A., Melchiorre, C., & Recanatini, M. (2009). U.S. Patent No. 7,589,219. Washington, DC: U.S. Patent and Trademark Office.

Mancini F, Bolognesi ML, Melchiorre C, Andrisano V. Investigation of the photostability properties of memoquin, a quinone derivative for the treatment of Alzheimer's disease. J Pharm Biomed Anal. 2009 Sep 8;50(2):164-70.

Kranjc A, Bongarzone S, Rossetti G, Biarnés X, Cavalli A, Bolognesi ML, Roberti M, Legname G, Carloni P. Docking Ligands on Protein Surfaces: The Case Study of Prion Protein. J Chem Theory Comput. 2009 Sep 8;5(9):2565-73.

Bolognesi ML, Bartolini M, Rosini M, Andrisano V, Melchiorre C. Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4312-5.

Cavalli A, Lizzi F, Bongarzone S, Brun R, Luise Krauth-Siegel R, Bolognesi ML. Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3031-5.

Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C. Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol. 2009 Jun;13(3):303-8.

Bolognesi ML, Banzi R, Minarini A, Melchiorre C, inventors; Bolognesi, Maria Laura, assignee. 2, 5-Bis-Diamine [1, 4] Benzoquinone-Derivatives. United States patent application US 11/917,560. 2009 Apr 9.

Bolognesi ML, Rosini M, Andrisano V, Bartolini M, Minarini A, Tumiatti V, Melchiorre C. MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. Curr Pharm Des. 2009;15(6):601-13.

Bolognesi ML, Cavalli A, Melchiorre C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics. 2009 Jan;6(1):152-62.

Tumiatti V, Milelli A, Minarini A, Rosini M, Bolognesi ML, Micco M, Andrisano V, Bartolini M, Mancini F, Recanatini M, Cavalli A, Melchiorre C. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. J Med Chem. 2008 Nov 27;51(22):7308-12.

Bolognesi ML, Calonghi N, Mangano C, Masotti L, Melchiorre C. Parallel synthesis and cytotoxicity evaluation of a polyamine-quinone conjugates library. J Med Chem. 2008 Sep 11;51(17):5463-7.

Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Melchiorre C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. Mini Rev Med Chem. 2008 Sep;8(10):960-7.

Rosini M, Simoni E, Bartolini M, Cavalli A, Ceccarini L, Pascu N, McClymont DW, Tarozzi A, Bolognesi ML, Minarini A, Tumiatti V, Andrisano V, Mellor IR, Melchiorre C. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem. 2008 Aug 14;51(15):4381-4.

Minarini A, Marucci G, Bellucci C, Giorgi G, Tumiatti V, Bolognesi ML, Matera R, Rosini M, Melchiorre C. Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics. Bioorg Med Chem. 2008 Aug 1;16(15):7311-20.

Tumiatti, V., Bolognesi, M. L., Minarini, A., Rosini, M., Milelli, A., Matera, R., & Melchiorre, C. (2008). Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update. Expert Opinion on Therapeutic Patents, 18(4), 387-401.

Bolognesi ML, Lizzi F, Perozzo R, Brun R, Cavalli A. Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2272-6.

Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008 Feb 14;51(3):347-72.

Cavalli, A., & Bolognesi, M. L. (2008). Structure-based design and synthesis of inhibitors of the trypanothione reductase enzyme from Trypanosoma cruzi. In XIX National Meeting on Medicinal Chemistry, Book of Abstracts (pp. 180-180). ITA.

Bolognesi ML, Cavalli A, Valgimigli L, Bartolini M, Rosini M, Andrisano V, Recanatini M, Melchiorre C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J Med Chem. 2007 Dec 27;50(26):6446-9.

Bartolini M, Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem. 2007 Nov 23;8(17):2152-61.

Mancini F, Bolognesi ML, Melchiorre C, Cavalli A, Andrisano V. Monolithic stationary phase coupled with coulometric detection: development of an ion-pair HPLC method for the analysis of quinone-bearing compounds. J Sep Sci. 2007 Nov;30(17):2935-42.

Bolognesi ML, Banzi R, Bartolini M, Cavalli A, Tarozzi A, Andrisano V, Minarini A, Rosini M, Tumiatti V, Bergamini C, Fato R, Lenaz G, Hrelia P, Cattaneo A, Recanatini M, Melchiorre C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J Med Chem. 2007 Oct 4;50(20):4882-97.

Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, Cattaneo A, Recanatini M, Melchiorre C. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl. 2007;46(20):3689-92.

Calonghi N, Pagnotta E, Parolin C, Mangano C, Bolognesi ML, Melchiorre C, Masotti L. A new EGFR inhibitor induces apoptosis in colon cancer cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):409-13.

Bolognesi, M. L., & Melchiorre, C. (2007). Strategie farmacologiche per il trattamento della malattia di Alzheimer. NEW ENTRIES IN PHARMACOLOGY, 2, 17-30.

Bolognesi, M. L., Lizzi, F., Andrisano, V., Bartolini, M., Hrelia, P., Tarozzi, A., ... & Melchiorre, C. (2007). Multi-target-directed drug design strategy: quinone derivatives designed to block amyloid-beta aggregation and to exert antioxidant effects. In 16th Camerino-Noordwijkrhout symposium" An overview of receptor chemistry" (pp. 117-bis). ITA.

Bolognesi, M. L., Cavalli, A., Andrisano, V., Bartolini, M., Minarini, A., & Melchiorre, C. (2007). Memoquine derivatives as potent inhibitors of AChE-induced amyloid-beta aggregation. In Programme and abtracts 16th Camerino-Noordwijkrhout symposium" An overview of receptor chemistry (pp. 117-117). ITA.

Rosini M, Bolognesi ML, Giardinà D, Minarini A, Tumiatti V, Melchiorre C. Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem. 2007;7(2):147-62.

Rosini M, Mancini F, Tarozzi A, Colizzi F, Andrisano V, Bolognesi ML, Hrelia P, Melchiorre C. Design, synthesis, and biological evaluation of substituted 2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamine related compounds as fructose-1,6-bisphosphatase inhibitors. Bioorg Med Chem. 2006 Dec 1;14(23):7846-53.

Antonello A, Tarozzi A, Morroni F, Cavalli A, Rosini M, Hrelia P, Bolognesi ML, Melchiorre C. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. J Med Chem. 2006 Nov 16;49(23):6642-5.

Bolognesi ML, Minarini A, Tumiatti V, Melchiorre C. Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. Mini Rev Med Chem. 2006 Nov;6(11):1269-74.

Minarini A, Bolognesi ML, Tumiatti V, Melchiorre C. Recent advances in the design and synthesis of prazosin derivatives. Expert Opin Drug Discov. 2006 Oct;1(5):395-407.

Capsoni, S., Andrisano, V., Bartolini, M., Bolognesi, M. L., Cavalli, A., Margotti, E., ... & Cattaneo, A. (2006). S4–04–04: Memoquin, a novel multifunctional compound for Alzheimer's disease: An up–date on preclinical studies. Alzheimer's & Dementia, 2, S73-S74.

Bolognesi, M. L., Minarini, A., Tumiatti, V., & Melchiorre, C. (2006). Progress in acetylcholinesterase inhibitors for Alzheimer’s disease. Expert Opinion on Therapeutic Patents, 16(6), 811-823.

Bartolini, M., Belluti, F., Bolognesi, M. L., Rosini, M., & Andrisano, V. (2006). In vitro methods for characterizing new multi-potent compounds for Alzheimer’s disease. In 9th International Geneve/Springfield Symposium on advances in Alzheimer Therapy, Abstract Book (pp. 32-32). sl.

Bolognesi, M. L., Banzi, R., Minarini, A., & Melchiorre, C. (2006). Process for preparation of 1, 4-benzoquinone-2, 5-diamines by reaction of amines with 1, 4-benzoquinones bearing leaving groups at the 2-and 5-positions.

Bolognesi, M. L., Antonello, A., Tarozzi, A., Rosini, M., Minarini, A., Tumiatti, V., ... & Melchiorre, C. (2006). One-molecule-multiple-target strategy: a novel multifunctional molecule designed to block EGF-r and to exert pro-apoptotic effects. In Atti del Congresso (pp. 172-172). sl.

Pistolozzi, M., Bolognesi, M. L., Melchiorre, C., & Bertucci, C. (2006). Polyaminoquinones Binding to Human Serum Albumin: a Biochromatography and Circular Dichroism Study. In XXII Congresso Nazionale della Società Chimica Italiana, SCI2006. ITA.

Parolin, C., Calonghi, N., Pagnotta, E., Mangano, C., Bolognesi, M. L., Melchiorre, C., & Masotti, L. (2006). A NEW EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR IN COLON CANCER CELLS. ITALIAN JOURNAL OF BIOCHEMISTRY, 55(1/2), 2.

Bolognesi, M. L., & Cavalli, A. (2006). Trypanothione reductase inhibitors as lead candidates to treat trypanosomatid diseases: recent advances and outlooks. Current trends in medicinal chemistry, Volume 4, 33-45.

Bolognesi ML, Andrisano V, Bartolini M, Cavalli A, Minarini A, Recanatini M, Rosini M, Tumiatti V, Melchiorre C. Heterocyclic inhibitors of AChE acylation and peripheral sites. Farmaco. 2005 Jun-Jul;60(6-7):465-73.

Rosini M, Andrisano V, Bartolini M, Bolognesi ML, Hrelia P, Minarini A, Tarozzi A, Melchiorre C. Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem. 2005 Jan 27;48(2):360-3.

Bolognesi ML, Andrisano V, Bartolini M, Banzi R, Melchiorre C. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. J Med Chem. 2005 Jan 13;48(1):24-7.

Tumiatti, V., Minarini, A., Rosini, M., Bolognesi, M. L., Marucci, G., Buccioni, M., ... & Melchiorre, C. (2005). Methoctramine-related polyamines as antinociceptive agents. In Second Joint Italian-Swiss Meeting on Medicinal Chemistry-Abstracts (pp. 125-P). Università di Modena e Reggio Emilia.

Minarini, A., Mellor, I., Bolognesi, M. L., Ogilvie, J., Rosini, M., Tumiatti, V., & Melchiorre, C. (2005). Methoctramine analogues inhibit responses to capsaicin in DRG neurons and cloned TRPV1. Trends in Drug Research, 76.

Capsoni, S., Cavalli, A., Andrisano, V., Bolognesi, M., Recanatini, M., Melchiorre, C., ... & Cattaneo, A. (2005). Memoquin: an up-date on preclinical studies. In Abstracts, 7th International Conference AD/PD 2005.

Capsoni, S., Cavalli, A., Andrisano, V., Bolognesi, M., Recanatini, M., Melchiorre, C., ... & Cattaneo, A. (2005). Memoquin: an up-date on preclinical studies. In Abstracts, 7th International Conference AD/PD 2005.

Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A, Melchiorre C. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem. 2004 Nov 18;47(24):5945-52.

Capsoni, S., Cavalli, A., Bolognesi, M., Bartolini, M., Andrisano, V., Melchiorre, C., ... & Cattaneo, A. (2004). Memoquin a new compound to attack Alzheimer’s disease: Preclinical studies. In Society for Neuroscience 2004, abstract 216.8.

Cavalli, A., Bolognesi, M., Bartolini, M., Andrisano, V., Melchiorre, C., Recanatini, M., ... & Cattaneo, A. (2004). Memoquin: a new compound to attack Alzheimer Disease on multiple fronts. In Abstracts 8th International Montreal/Springfield Symposium on Advances in Alzheimer Therapy.

Marucci, G., Novi, F., Banzi, R., Bolognesi, M. L., Buccioni, M., Minarini, A., ... & Melchiorre, C. (2004). Polyamines may modulate both G protein-coupled receptors and G proteins. Medicinal chemistry research, 13(1-2), 63-73.

Cavalli, A., Bolognesi, M. L., Bartolini, M., Andrisano, V., Melchiorre, C., Recanatani, M., ... & Cattaneo, A. (2004). P1-339 Memoquin: a new therapeutic poly-agent for Alzheimer's disease. Neurobiology of Aging, (25), S194.

Rosini M, Antonello A, Cavalli A, Bolognesi ML, Minarini A, Marucci G, Poggesi E, Leonardi A, Melchiorre C. Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. J Med Chem. 2003 Nov 6;46(23):4895-903.

Bolognesi ML, Cavalli A, Andrisano V, Bartolini M, Banzi R, Antonello A, Rosini M, Melchiorre C. Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. Farmaco. 2003 Sep;58(9):917-28.

Melchiorre C, Antonello A, Banzi R, Bolognesi ML, Minarini A, Rosini M, Tumiatti V. Polymethylene tetraamine backbone as template for the development of biologically active polyamines. Med Res Rev. 2003 Mar;23(2):200-33.

Bolognesi ML, Bixel MG, Marucci G, Bartolini M, Krauss M, Angeli P, Antonello A, Rosini M, Tumiatti V, Hucho F, Melchiorre C. Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 3. Effect of inserting the tetraamine backbone into a macrocyclic structure. J Med Chem. 2002 Jul 18;45(15):3286-95.

Rosini M, Bixel MG, Marucci G, Budriesi R, Krauss M, Bolognesi ML, Minarini A, Tumiatti V, Hucho F, Melchiorre C. Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms. J Med Chem. 2002 Apr 25;45(9):1860-78.

Melchiorre C, Bolognesi ML, Budriesi R, Ghelardini C, Chiarini A, Minarini A, Rosini M, Tumiatti V, Wade EJ. Design, synthesis, and biological activity of methoctramine-related polyamines as putative G(i) protein activators. J Med Chem. 2001 Nov 22;44(24):4035-8.

Bixel, M. G., Weise, C., Krauss, M., Rosini, M., Bolognesi, M. L., Melchiorre, C., & Hucho, F. (2001, June). Cyclic polyamine derivatives bind with high affinity to the nicotinic acetylcholine receptor. In JOURNAL OF NEUROCHEMISTRY (Vol. 77, pp. 49-50). PO BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND: BLACKWELL SCIENCE LTD.

Bixel MG, Weise C, Bolognesi ML, Rosini M, Brierly MJ, Mellor IR, Usherwood PN, Melchiorre C, Hucho F. Location of the polyamine binding site in the vestibule of the nicotinic acetylcholine receptor ion channel. J Biol Chem. 2001 Mar 2;276(9):6151-60.

Bixel MG, Krauss M, Weise C, Bolognesi ML, Rosini M, Usherwood PN, Melchiorre C, Hucho F. Binding of polyamine-containing toxins in the vestibule of the nicotinic acetylcholine receptor ion channel. Farmaco. 2001 Jan-Feb;56(1-2):133-5.

Budriesi R, Cacciaguerra S, Toro RD, Bolognesi ML, Chiarini A, Minarini A, Rosini M, Spampinato S, Tumiatti V, Melchiorre C. Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines. Br J Pharmacol. 2001 Mar;132(5):1009-16.

Bolognesi ML, Marucci G, Angeli P, Buccioni M, Minarini A, Rosini M, Tumiatti V, Melchiorre C. Analogues of prazosin that bear a benextramine-related polyamine backbone exhibit different antagonism toward alpha1-adrenoreceptor subtypes. J Med Chem. 2001 Feb 1;44(3):362-71.

Bolognesi ML, Andrisano V, Bartolini M, Minarini A, Rosini M, Tumiatti V, Melchiorre C. Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors. J Med Chem. 2001 Jan 4;44(1):105-9.

Tumiatti V, Angeli P, Andrisano V, Bolognesi ML, Cavalli A, Marucci G, Minarini A, Recanatini M, Rosini M, Melchiorre C. [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]-trimethylammonium (McN-A-343)-related compounds. Effect of the butynyl chain inclusion into an aromatic unit on the potency for muscarinic receptors. Bioorg Med Chem. 2000 Apr;8(4):681-9.

D'Agostino G, Bolognesi ML, Lucchelli A, Vicini D, Balestra B, Spelta V, Melchiorre C, Tonini M. Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptor subtype. Br J Pharmacol. 2000 Feb;129(3):493-500.

Melchiorre C, Angeli P, Bolognesi ML, Chiarini A, Giardinà D, Gulini U, Leonardi A, Marucci G, Minarini A, Pigini M, Quaglia W, Rosini M, Tumiatti V. Alpha 1-adrenoreceptor antagonists bearing a quinazoline or a benzodioxane moiety. Pharm Acta Helv. 2000 Mar;74(2-3):181-90.

Bixel MG, Krauss M, Liu Y, Bolognesi ML, Rosini M, Mellor IS, Usherwood PN, Melchiorre C, Nakanishi K, Hucho F. Structure-activity relationship and site of binding of polyamine derivatives at the nicotinic acetylcholine receptor. Eur J Biochem. 2000 Jan;267(1):110-20.

Rosini M, Budriesi R, Bixel MG, Bolognesi ML, Chiarini A, Hucho F, Krogsgaard-Larsen P, Mellor IR, Minarini A, Tumiatti V, Usherwood PN, Melchiorre C. Design, synthesis, and biological evaluation of symmetrically and unsymmetrically substituted methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. J Med Chem. 1999 Dec 16;42(25):5212-23.

Bolognesi ML, Budriesi R, Cavalli A, Chiarini A, Gotti R, Leonardi A, Minarini A, Poggesi E, Recanatini M, Rosini M, Tumiatti V, Melchiorre C. WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors. J Med Chem. 1999 Oct 7;42(20):4214-24.

Bixel, M. G., Krauss, M., Weise, C., Bolognesi, M. L., Rosini, M., Melchiorre, C., & Hucho, F. (1999, January). Localisation of the polymethylene tetramine binding site on the nicotinic acetylcholine receptor. In JOURNAL OF NEUROCHEMISTRY (Vol. 73, pp. S148-S148). 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS.

Bolognesi ML, Budriesi R, Chiarini A, Poggesi E, Leonardi A, Melchiorre C. Design, synthesis, and biological activity of prazosin-related antagonists. Role of the piperazine and furan units of prazosin on the selectivity for alpha1-adrenoreceptor subtypes. J Med Chem. 1998 Nov 19;41(24):4844-53.

Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, Rosini M, Tumiatti V, Recanatini M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J Med Chem. 1998 Oct 22;41(22):4186-9.

Bolognesi ML, Minarini A, Budriesi R, Cacciaguerra S, Chiarini A, Spampinato S, Tumiatti V, Melchiorre C. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. J Med Chem. 1998 Oct 8;41(21):4150-60.

Barbier P, Colelli A, Bolognesi ML, Minarini A, Tumiatti V, Corsini GU, Melchiorre C, Maggio R. Antagonist binding profile of the split chimeric muscarinic m2-trunc/m3-tail receptor. Eur J Pharmacol. 1998 Aug 21;355(2-3):267-74.

Melchiorre, C., Bolognesi, M. L., Budriesi, R., Chiarini, A., Giardinà, D., Minarini, A., ... & Leonardi, A. (1998). Search for selective antagonists at α1-adrenoreceptors: neutral or negative antagonism?. Il Farmaco, 53(4), 278-286.

Opioid Antagonist Activity of Naltrexone-Derived Bivalent Ligands: Importance of a Properly Oriented Molecular Scaffold To Guide “Address” Recognition at κ Opioid Receptors

Melchiorre, C., Angeli, P., Bolognesi, M. L., Budriesi, R., Cacciaguerra, S., Chiarini, A., ... & Tumiatti, V. (1996). Tetraamines as lead compounds for the design of neurotransmitter receptor ligands: Focus on α-adrenergic and muscarinic receptors recognition. In Pharmacochemistry Library (Vol. 24, pp. 321-336). Elsevier.

Chiarini A, Budriesi R, Bolognesi ML, Minarini A, Melchiorre C. In vitro characterization of tripitramine, a polymethylene tetraamine displaying high selectivity and affinity for muscarinic M2 receptors. Br J Pharmacol. 1995 Apr;114(7):1507-17.

Recanatini M, Tumiatti V, Budriesi R, Chiarini A, Sabatino P, Bolognesi ML, Melchiorre C. Synthesis, muscarinic blocking activity and molecular modeling studies of 4-DAMP-related compounds. Bioorg Med Chem. 1995 Mar;3(3):267-77.

Melchiorre C, Romualdi P, Bolognesi ML, Donatini A, Ferri S. Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas. Eur J Pharmacol. 1994 Nov 14;265(1-2):93-8.

Minarini A, Bolognesi ML, Budriesi R, Canossa M, Chiarini A, Spampinato S, Melchiorre C. Design, synthesis, and biological activity of methoctramine-related tetraamines bearing an 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4] benzodiazepin-6-one moiety: structural requirements for optimum occupancy of muscarinic receptor subtypes as revealed by symmetrical and unsymmetrical polyamines. J Med Chem. 1994 Sep 30;37(20):3363-72.

Maggio R, Barbier P, Bolognesi ML, Minarini A, Tedeschi D, Melchiorre C. Binding profile of the selective muscarinic receptor antagonist tripitramine. Eur J Pharmacol. 1994 Aug 16;268(3):459-62.

Melchiorre C, Bolognesi ML, Chiarini A, Minarini A, Spampinato S. Synthesis and biological activity of some methoctramine-related tetraamines bearing a 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepin-6-one moiety as antimuscarinics: a second generation of highly selective M2 muscarinic receptor antagonists. J Med Chem. 1993 Nov 12;36(23):3734-7.

Tumiatti, V., Recanatini, M., Minarini, A., Melchiorre, C., Chiarini, A., Budriesi, R., & Bolognesi, M. (1992). Affinity and selectivity at M~ 2 and M~ 3 muscarinic receptor subtypes of cyclic and open oxygenated analogues of 4-DAMP. Farmaco, 47, 1133-1133.